The validation of surrogate endpoints in meta-analyses of randomized experiments

Recommendations

Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points
The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials
The evaluation of surrogate endpoints.
A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint

Cited in

(67)

Choice of units of analysis and modeling strategies in multilevel hierarchical models
Principal stratification in causal inference
Exploring the Relationship Between Surrogates and Clinical Outcomes: Analysis of Individual Patient Data vs. Meta-regression on Group-Level Summary Statistics
Using earlier measures in a longitudinal sequence as a potential surrogate for a later one
Exploring the relationship between the causal-inference and meta-analytic paradigms for the evaluation of surrogate endpoints
Bayesian meta-analytical methods to incorporate multiple surrogate endpoints in drug development process
Differences in surrogate threshold effect estimates between original and simplified correlation-based validation approaches
Prentice's Approach and the Meta-Analytic Paradigm: A Reflection on the Role of Statistics in the Evaluation of Surrogate Endpoints
Bayesian adaptive trial design for a newly validated surrogate endpoint
Predicting treatment effect from surrogate endpoints and historical trials: an extrapolation involving probabilities of a binary outcome or survival to a specific time
A shrinkage approach for estimating a treatment effect using intermediate biomarker data in clinical trials
A general framework to assess complex heterogeneity in the strength of a surrogate marker
Design and estimation for evaluating principal surrogate markers in vaccine trials
Taking advantage of sampling designs in spatial small-area survey studies
Fast, effective, and coherent time series modelling using the sparsity-ranked Lasso
Copula-based pairwise estimator for quantile regression with hierarchical missing data
Linear increment in efficiency with the inclusion of surrogate endpoint
On the relationship between the causal-inference and meta-analytic paradigms for the validation of surrogate endpoints
Center-within-trial versus trial-level evaluation of surrogate endpoints
Comparative assessment of trial-level surrogacy measures for candidate time-to-event surrogate endpoints in clinical trials
Links between causal effects and causal association for surrogacy evaluation in a Gaussian setting
Validation of surrogate endpoints in cancer clinical trials via principal stratification with an application to a prostate cancer trial
Assessing a surrogate predictive value: a causal inference approach
Validation of surrogate markers in multiple randomized clinical trials with repeated measurements
Evaluating time-to-event surrogates for time-to-event true endpoints: an information-theoretic approach based on causal inference
Predictive probability of success using surrogate endpoints
Comparing biomarkers as principal surrogate endpoints
Robust Approach to Combining Multiple Markers to Improve Surrogacy
Discussion on ``Surrogate measures and consistent surrogates
Meta-analysis for surrogacy: accelerated failure time models and semicompeting risks modeling
Surrogate Marker Evaluation from an Information Theory Perspective
A Measure of the Proportion of Treatment Effect Explained by a Surrogate Marker
Confidence intervals and statistical power of the ``Validation ratio for surrogate or intermediate endpoints
A Bayesian approach to surrogacy assessment using principal stratification in clinical trials
Bayesian hierarchical meta-analytic methods for modeling surrogate relationships that vary across treatment classes using aggregate data
A joint frailty‐copula model for meta‐analytic validation of failure time surrogate endpoints in clinical trials
A perspective on surrogate endpoints in controlled clinical trials
Bivariate network meta-analysis for surrogate endpoint evaluation
One-step validation method for surrogate endpoints using data from multiple randomized cancer clinical trials with failure-time endpoints
On Assessing Surrogacy in a Single Trial Setting Using a Semicompeting Risks Paradigm
Flexible surrogate marker evaluation from several randomized clinical trials with continuous endpoints, using R and SAS
Exploring and validating surrogate endpoints in colorectal cancer
Statistical evaluation of surrogate endpoints with examples from cancer clinical trials
Statistical identifiability and the surrogate endpoint problem, with application to vaccine trials
Identifying candidate secondary endpoints in semi-competing risk time-to-event data using an integrated analytical framework
A simple meta-analytic approach for using a binary surrogate endpoint to predict the effect of intervention on true endpoint
Validation of Surrogate end Points in Multiple Randomized Clinical Trials with Failure Time end Points
Validation of Surrogate Markers in Multiple Randomized Clinical Trials with Repeated Measurements: Canonical Correlation Approach
On the relationship between association and surrogacy when both the surrogate and true endpoint are binary outcomes
Sensitivity analysis for evaluating principal surrogate endpoints relaxing the equal early clinical risk assumption
Assurance in vaccine efficacy clinical trial design based on immunological responses
The Evaluation of Multiple Surrogate Endpoints
The evaluation of surrogate endpoints.
Criteria for the Validation of Surrogate Endpoints in Randomized Experiments
An efficient algorithm to assess multivariate surrogate endpoints in a causal inference framework
Pairwise Fitting of Mixed Models for the Joint Modeling of Multivariate Longitudinal Profiles
Advances in medical statistics arising from the AIDS epidemic
RISE: two-stage rank-based identification of high-dimensional surrogate markers applied to vaccinology
Efficient testing using surrogate information
Surrogate marker evaluation: a tutorial using R
Surrogate endpoints in drug development: a review of statistical and regulatory perspectives and applications
Robust evaluation of longitudinal surrogate markers with censored data
Validation of Surrogate Endpoints in Multiple Randomized Clinical Trials with Discrete Outcomes
Simplified modeling strategies for surrogate validation with multivariate failure-time data
The meta-analytic framework for the evaluation of surrogate endpoints in clinical trials
Validation of a longitudinal marker as a surrogate using mediation analysis and joint modeling: evolution of the PSA as a surrogate of the disease-free survival
A new frequentist implementation of the Daniels and Hughes bivariate meta-analysis model for surrogate endpoint evaluation

This page was built for publication: The validation of surrogate endpoints in meta-analyses of randomized experiments

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q4489920)